Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo

Journal of Drug Targeting

Volumn 20, Issue 10, 2012, Pages 883-896

  Dwivedi, Pankaj ^a   Kansal, Shaswat ^a   Sharma, Monika ^a   Shukla, Rahul ^a   Verma, Ashwini ^a   Shukla, Prashant ^a   Tripathi, Priyanka ^a   Gupta, Pramod ^a   Saini, Deepika ^a   Khandelwal, Kiran ^a   Verma, Rahul ^a   Dwivedi, Anil Kumar ^a   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

4 sulfated N acetyl galactosamine; gelatin nanoparticles; macrophages; mannose receptors

Indexed keywords

EID: 84868356543     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.725169     Document Type: Article

References (46)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. (2002). Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release, 79, 29-40. (Pubitemid 34164159)
2. Chawla S, Kumar S, Garg M, Kumar R, Roy R, Gupta RK. (2004). Metabolite pattern of Cysticercus cellulosae metacestode from different predilection sites of swine using proton magnetic resonance spectroscopy. Parasite, 11, 161-167. (Pubitemid 40021974)
3. Chellat F, Merhi Y, Moreau A, Yahia L. (2005). Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 26, 7260-7275. (Pubitemid 41133578)
4. Chen CL, Wang YM, Liu CF, Wang JY. (2008). The effect of watersoluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials, 29, 2173-2182.
5. Coester CJ, Langer K, van Briesen H, Kreuter J. (2000). Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul, 17, 187-193. (Pubitemid 30135796)
6. Cummings J, Willmott N, Marley E, Smyth J. (1991). Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition. Biochem Pharmacol, 41, 1849-1854.
7. Fiete D, Baenziger JU. (1997). Isolation of the SO4-4-GalNAcbeta1,4Glc NAcbeta1,2Manalpha-specific receptor from rat liver. J Biol Chem, 272, 14629-14637. (Pubitemid 27251725)
8. Fiete D, Srivastava V, Hindsgaul O, Baenziger JU. (1991). A hepatic reticuloendothelial cell receptor specific for SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha that mediates rapid clearance of lutropin. Cell, 67, 1103-1110. (Pubitemid 121001523)
9. Fiete DJ, Beranek MC, Baenziger JU. (1998). A cysteine-rich domain of the "mannose" receptor mediates GalNAc-4-SO4 binding. Proc Natl Acad Sci USA, 95, 2089-2093.
10. Gupta GK, Kansal S, Misra P, Dube A, Mishra PR. (2009). Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech, 10, 1343-1347.
11. Hallab NJ, Bundy KJ, O'Connor K, Clark R, Moses RL. (1995). Cell adhesion to biomaterials: correlations between surface charge, surface roughness, adsorbed protein, and cell morphology. J Long Term Eff Med Implants, 5, 209-231. (Pubitemid 26109146)
12. Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid St M, 6, 319-327. (Pubitemid 36238389)
13. Harris N, Super M, Rits M, Chang G, Ezekowitz RA. (1992). Characterization of the murine macrophage mannose receptor: demonstration that the downregulation of receptor expression mediated by interferon-gamma occurs at the level of transcription. Blood, 80, 2363-2373.
14. Hartmann G, Vassileva V, Piquette-Miller M. (2005). Impact of endotoxininduced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos, 33, 820-828. (Pubitemid 40686636)
15. Jahanshahi M, Sanati MH, Hajizadeh S, Babaei Z. (2008). Gelatin nanoparticle fabrication and optimization of the particle size. Physica Status Solidi (a), 205, 2898-2902.
16. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. (2008). Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine, 4, 41-48. (Pubitemid 351324205)
17. Jameela SR, Jayakrishnan A. (1995). Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle. Biomaterials, 16, 769-775.
18. Kansal S, Tandon R, Dwivedi P, Misra P, Verma PR, Dube A, Mishra PR. (2012). Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother. DOI: 10.1093/jac/dks286.
19. Kaul G, Amiji M. (2002). Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res, 19, 1061-1067. (Pubitemid 34804251)
20. Kommareddy S, Amiji M. (2007). Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine, 3, 32-42. (Pubitemid 46428185)
21. Leo E, Cameroni R, Forni F. (1999). Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm, 180, 23-30. (Pubitemid 29131439)
22. Leteux C, Chai W, Loveless RW, Yuen CT, Uhlin-Hansen L, Combarnous Y, Jankovic M, Maric SC, Misulovin Z, Nussenzweig MC, Feizi T. (2000). The cysteine-rich domain of the macrophage mannose receptor is a multispecific lectin that recognizes chondroitin sulfates A and B and sulfated oligosaccharides of blood group Lewis(a) and Lewis(x) types in addition to the sulfated N-glycans of lutropin. J Exp Med, 191, 1117-1126. (Pubitemid 30207675)
23. Liu J, Teng L, Liu C, Hu L, Wang Y, Liu H, Wang F. (2009). Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by chemical modification with polysaccharide and attenuation effects on radiation-induced inflammatory cytokine expression in vitro. J Drug Target, 17, 216-224.
24. Liu Y, Misulovin Z, Bjorkman PJ. (2001). The molecular mechanism of sulfated carbohydrate recognition by the cysteine-rich domain of mannose receptor. J Mol Biol, 305, 481-490. (Pubitemid 33032855)
25. Marty JJ, Oppenheim RC, Speiser P. (1978). Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv, 53, 17-23.
26. Mitchell JP, Roberts KD, Langley J, Koentgen F, Lambert JN. (1999). A direct method for the formation of peptide and carbohydrate dendrimers. Bioorg Med Chem Lett, 9, 2785-2788. (Pubitemid 29481162)
27. Mitra S, Gaur U, Ghosh PC, Maitra AN. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release, 74, 317-323. (Pubitemid 32727639)
28. Mishra PR, Al Shaal L, Mler RH, Keck CM. (2009). Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm, 371, 182-189.
29. Mosser DM, Brittingham A. (1997). Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology, 115 Suppl, S9-23. (Pubitemid 28166130)
30. Mukhopadhyay A, Basu SK. (2003). Intracellular delivery of drugs to macrophages. Adv Biochem Eng Biotechnol, 84, 183-209.
31. Nahar M, Dubey V, Mishra D, Mishra PK, Dube A, Jain NK. (2010). In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target, 18, 93-105.
32. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. (2009). Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target, 17, 777-787.
33. Owens DE 3rd, Peppas NA. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm, 307, 93-102. (Pubitemid 41773257)
34. Phillips R, Svensson M, Aziz N, Maroof A, Brown N, Beattie L, Signoret N, Kaye PM. (2010). Innate killing of Leishmania donovani by macrophages of the splenic marginal zone requires IRF-7. PLoS Pathog, 6, e1000813.
35. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Krer SD, Knuth A, Pascolo S. (2010). Particle size and activation threshold: a new dimension of danger signaling. Blood, 115, 4533-4541.
36. Roseman DS, Baenziger JU. (2000). Molecular basis of lutropin recognition by the mannose/GalNAc-4-SO4 receptor. Proc Natl Acad Sci USA, 97, 9949-9954.
37. Saraogi GK, Sharma B, Joshi B, Gupta P, Gupta UD, Jain NK, Agrawal GP. (2011). Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target, 19, 219-227.
38. Sett R, Basu N, Ghosh AK, Das PK. (1992). Potential of doxorubicin as an antileishmanial agent. J Parasitol, 78, 350-354.
39. Sett R, Sarkar K, Das PK. (1993). Macrophage-directed delivery of doxorubicin conjugated to neoglycoprotein using leishmaniasis as the model disease. J Infect Dis, 168, 994-999. (Pubitemid 23282576)
40. Shao JY, Hochmuth RM. (1997). The resistance to flow of individual human neutrophils in glass capillary tubes with diameters between 4.65 and 7.75 microns. Microcirculation, 4, 61-74. (Pubitemid 127717667)
41. Shukla P, Gupta G, Singodia D, Shukla R, Verma AK, Dwivedi P, Kansal S, Mishra PR. (2010). Emerging trend in nano-engineered polyelectrolyte-based surrogate carriers for delivery of bioactives. Expert Opin Drug Deliv, 7, 993-1011.
42. Singodia D, Verma A, Verma RK, Mishra PR. (2012). Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: an application in drug delivery. Nanomedicine, 8, 468-477.
43. Wadhwa MS, Rice KG. (1995). Receptor mediated glycotargeting. J Drug Target, 3, 111-127.
44. Wang JJ, Sung KC, Hu OY, Yeh CH, Fang JY. (2006). Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Control Release, 115, 140-149. (Pubitemid 44559707)
45. Weber C, Coester C, Kreuter J, Langer K. (2000). Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm, 194, 91-102.
46. Wu Y, Tibrewal N, Birge RB. (2006). Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol, 16, 189-197.